Inställningar

Split view

Short keys for navigating in split view

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Dark Mode

Set dark mode to MFN.se

Sound

Plays a notification sound when new press release is published in the current feed

Intresserad av platformen MFN för nyhetsdistribution?

Söndag 28 Juni | 07:43:38 Europe / Stockholm

Svenska | English

Investor Relations

Public Relations

Redeye

Bifogade filer

Mendus Q1 2023 - Opportunities and hurdles

Prenumeration

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

Mendus Q1 2023 - Opportunities and hurdles

2023-05-12 13:28:00

Redeye provides its comment on Mendus’ Q1 2023 report. We believe the company has a solid plan for continued clinical development of vididencel and ilixadencel. However, uncertainties around financing these trials cast a shadow over the investment case.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/